Matt WillemsenFDA Approves Zurzuvae (Zuranolone) – First Oral Treatment for Postpartum Depression
The FDA has approved Zurzuvae, a novel oral treatment for postpartum depression. Clinical studies have confirmed its effectiveness, but warnings include potential driving impairment and common side effects. This medication offers a new option beyond the previously available IV treatments.
https://scitechdaily.com/fda-approves-zurzuvae-zuranolone-first-oral-treatment-for-postpartum-depression/ #postpartum #depression #FDA #zurzuvae #oral #treatment
The FDA has approved Zurzuvae, a novel oral treatment for postpartum depression. Clinical studies have confirmed its effectiveness, but warnings include potential driving impairment and common side effects. This medication offers a new option beyond the previously available IV treatments.
https://scitechdaily.com/fda-approves-zurzuvae-zuranolone-first-oral-treatment-for-postpartum-depression/ #postpartum #depression #FDA #zurzuvae #oral #treatment
FDA Approves Zurzuvae (Zuranolone) – First Oral Treatment for Postpartum Depression
On August 4, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Unt